Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07465432 · ClinicalTrials.gov registry record · Phase 4
Pharmacokinetic Analysis of Cefiderocol in Patients With Acute Burn Injuries
A Phase 4 study of Drug Clearance After Severe Burn Injury, sponsored by University of Tennessee.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT07465432 is a Phase 4 study of Drug Clearance After Severe Burn Injury that is actively recruiting participants, run by University of Tennessee. The registered enrollment target is 12 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07465432, a Phase 4 study of Drug Clearance After Severe Burn Injury, is actively recruiting participants, sponsored by University of Tennessee.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
Cefiderocol is a powerful, broad spectrum antibiotic approved to treat hospital-acquired or ventilator associated pneumonia and urinary tract infections. Although cefiderocol has labeled dosing recommendations, including augmented renal clearance, patients with burn injury remain an unstudied population at high risk for MDR pathogens. The primary objective of this study is to evaluate the pharmacokinetic principles of cefiderocol in patients after acute burn injury. Findings from this study will determine the dose and interval necessary to maintain therapeutic concentrations of cefiderocol in patients after burn injury for adequate bactericidal activity, prevention of resistance, and treatment outcomes.
Conditions Studied
Interventions
- DRUG Cefiderocol
Study Locations (1)
Tennessee
- Regional One Health - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2026-02-16 |
| Est. Completion | 2027-02-28 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07465432
The ClinicalTrials.gov registry entry for NCT07465432 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Tennessee, which has 96 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Drug Clearance After Severe Burn Injury appearing as the primary indexed condition, and to 1 intervention - of which Cefiderocol is the first listed.
NCT07465432 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT07465432 about?
NCT07465432 is a clinical study titled "Pharmacokinetic Analysis of Cefiderocol in Patients With Acute Burn Injuries". Cefiderocol is a powerful, broad spectrum antibiotic approved to treat hospital-acquired or ventilator associated pneumonia and urinary tract infections. Although cefiderocol has labeled dosing recommendations, including augmented renal clearance, patients with burn injury remain an unstudied popula...
What is the current status of trial NCT07465432?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 12 participants. The study started on 2026-02-16. Estimated completion is 2027-02-28.
What conditions does trial NCT07465432 study?
This clinical trial studies the following conditions: Drug Clearance After Severe Burn Injury.
What interventions are being tested in trial NCT07465432?
The interventions under investigation include: Cefiderocol (DRUG).
Who is sponsoring clinical trial NCT07465432?
This trial is sponsored by University of Tennessee, which has 96 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07465432 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.